Excited to announce my new role as first female program director for the KU Wichita Internal Medicine residency. It’s an honor and a privilege. @KUSM_Wichita
Thank you @AcpKansas for the honor of being named Kansas Laureate. Pictured here with two greats: last years winner, Dr. Scott Smiley and the ever amazing Dr. Donna Sweet @DonnaESweet1
#CVD cost the #EU an estimated €282 billion in 2021. Health and long-term care accounted for €155 billion (55%) of these costs, equalling 11% of EU health expenditure. The analysis was a collaborative effort by @escardio and @UniofOxford ⬇️
#ESCCongress
Presented at #ESCCongress:
In this randomized trial, extracorporeal life support did not improve 30-day survival as compared with usual care in patients with acute myocardial infarction complicated by cardiogenic shock.
Full ECLS-SHOCK trial results: https://t.co/gsxcdgQpg9
Upgrade to cardiac resynchronisation therapy with a defibrillator (CRT-D) reduces morbidity & mortality and improves left ventricular reverse remodelling compared to an ICD in select patients with #HeartFailure and #HFrEF and intermittent or permanent RV pacing ⬇️
#ESCCongress BUDAPEST CRT Upgrade trial
The traditional Chinese medicine qiliqiangxin reduces hospitalisation for #HeartFailure and CV death in patients with #HF and a reduced ejection fraction (#HFrEF) ⬇️
#ESCCongress QUEST trial
Only one take home message you need to take home from #ESCCongress
🛑Don’t start tx of diabetes with metformin!
✅ start tx with GLPRA or SGLTi
2023 ESC Guidelines of tx of patients with CVD and DM
@robmentz presenting at #ESCCongress HEART-FID trial: ferric carboxymaltose in HFrEF & iron deficiency
🔺1/3 💃🏻
🔺safe therapy by this trial
🔺did not meet endpoint prespecified but ⬇️☠️+HF 🏥+ ⬆️6MWD
🔺FCM use in HFrEF: what will you do?
@DukeHeartCenter
Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial:
Quadruple GDMT optimization in HFrEF can save a substantial # of lives
Vital need to:
OPTIMIZE-HF
IMPROVE-HF
GET WITH THE GUIDELINES-HF
TARGET-HF
EPIC-HF
PROMPT-HF
STRONG-HF
BETTER CARE-HF
IMPLEMENT-HF
Every eligible patient, every time, every care setting
🎉 Happy to have presented my research at #SGIM2023 🩺🧬📊
💻🤝 Extremely glad to network with colleagues from around the world and catching up with our home faculty, Professor Badgett.
@AasthaBharwad@KUSM_Wichita@SocietyGIM